Trials / Recruiting
RecruitingNCT07016152
An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae Vaccine (CHO-V08) in Healthy Adults
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Cho Pharma Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
CHO-V08 is currently being developed as a prevention vaccine against nosocomial and community-acquired infection caused by hypervirulent Klebsiella pneumoniae K1 and K2 serotypes. The goal of study (KLEBBI-001) is to evaluate the safety, reactogenicity, and immunogenicity of the preventive vaccine of CHO-V08 in healthy volunteers aged from 18 to 50 years old.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Glyconjugate Klebsiella pneumoniae bivalent vaccine | CHO-V08 is a glycoconjugate bivalent vaccine in sterile suspension. |
Timeline
- Start date
- 2025-06-26
- Primary completion
- 2026-11-05
- Completion
- 2027-04-10
- First posted
- 2025-06-11
- Last updated
- 2025-06-27
Locations
1 site across 1 country: Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07016152. Inclusion in this directory is not an endorsement.